Insider · CIK 0002123546
Nicola Deidre Petal Greenway
Files at TAK (TAKEDA PHARMACEUTICAL CO LTD). First filing Aug 12, 2026, latest Aug 19, 2026.
In brief
Nicola Deidre Petal Greenway files SEC Form 4 as officer at TAK (TAKEDA PHARMACEUTICAL CO LTD). Since Aug 12, 2026, Nicola Deidre Petal Greenway has reported 0 open-market buys worth $0 and 3 open-market sells worth $957k, the latest filed on Aug 19, 2026.
A track record needs three past buys with six months of prices behind them; Nicola Deidre Petal Greenway has 0, so none is measured yet.
The newest scored trade: sold $235k of TAK on Aug 18, 2026, filed Aug 19, 2026, scored 48 (moderate). In the last 12 months: 0 buys worth $0 and 3 sells worth $957k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TAK: TAKEDA PHARMACEUTICAL CO LTD
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | TAKEDA PHARMACEUTICAL CO LTD | $235k 12,980 shares | -24% | +36% from low-4% from high | |
| 59Moderate | TAKEDA PHARMACEUTICAL CO LTD | $606k 34,603 shares | -37% | +33% from low-7% from high | |
| 45Moderate | TAKEDA PHARMACEUTICAL CO LTD | $116k 6,774 shares | -11% | +33% from low-7% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 14, 2026 | TAK Takeda Pharmaceutical Company Limited | 12,980 0.01% of outstanding | $226k | Aug 14, 2026 | $721k |
| Aug 6, 2026 | TAK Takeda Pharmaceutical Company Limited | 34,603 0.02% of outstanding | $579k | Aug 7, 2026 | $123k |
| Jul 13, 2026 | TAK Takeda Pharmaceutical Company Limited | 7,348 0.01% of outstanding | $123k | Jul 13, 2026 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Shares | -12,980 | $18.11 | $235k | 40,049 | Aug 19, 2026 |
| Aug 10, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Shares | -975 | $17.50 | $17k | 93,431 | Aug 12, 2026 |
| Aug 10, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Shares | -6,774 | $17.10 | $116k | 53,029 | Aug 12, 2026 |
| Aug 10, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Shares | -33,628 | $17.51 | $589k | 59,803 | Aug 12, 2026 |
| Jul 1, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | AGrant or award American Depositary Shares | +22,570 | $0.00 | $0 | 94,406 | Jul 6, 2026 |
Questions about Nicola Deidre Petal Greenway
Answered from the filings on this page, as of the latest one.
Is Nicola Deidre Petal Greenway buying or selling?
In the last 12 months Nicola Deidre Petal Greenway reported 0 open-market buys worth $0 and 3 open-market sells worth $957k on SEC Form 4; the latest was sold $235k of TAK on Aug 18, 2026. Grants, option exercises and tax withholding are not counted.
How did Nicola Deidre Petal Greenway's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nicola Deidre Petal Greenway has 0.
Where does Nicola Deidre Petal Greenway file Form 4?
Nicola Deidre Petal Greenway has filed Form 4 at TAK (TAKEDA PHARMACEUTICAL CO LTD) as Chief Human Resources Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.